- Implied Volatility 14.49% ( -10.91%)
- Historical Volatility 34.16%
- IV Percentile 4%
- IV Rank 19.23%
- IV High 51.07% on 03/16/23
- IV Low 5.78% on 07/21/23
- Put/Call Vol Ratio 999.99
- Today's Volume 3
- Volume Avg (30-Day) 3
- Put/Call OI Ratio 0.58
- Today's Open Interest 126
- Open Int (30-Day) 120
Price PerformanceSee More
|Period||Period Low||Period High||Performance|
| || |
+3.59 (+14.33%)since 11/08/23
| || |
-0.92 (-3.11%)since 09/08/23
| || |
-1.20 (-4.02%)since 12/08/22
Most Recent StoriesMore News
2023 could be a year of heightened biotech dealmaking activity
Wall Street wrapped up a winning April buoyed by better-than-expected earnings and easing of banking fears. Cooling inflation added to the strength. The Dow Jones logged its best monthly gain since January,...
April brings with it seasonal tailwinds for the equity world. Digital Assets, Sugar, Platinum, Biotech and Homebuilding were clear winners in the month.
President Joe Biden recently announced his reelection bid. These ETF areas may benefit on that campaign launch.
Wall Street offered a flat performance last week. Biotech, platinum and home building were some of the areas that won last week.
Biotech and cryptocurrency -- two ETF areas outperformed last week.
The biotech corner of the broad healthcare sector outperformed last week on speculation over a takeover bid for Global Blood Therapeutics.
BBC, CNCR, XBI, BBP, and SBIO are part of Zacks top Analyst Blog.
Biotech, the downtrodden segment of the market, has made a solid comeback on bargain hunting.
These funds can take some of the risks out of these exciting but sometimes dangerous sectors.